Ono A, Isaka M, Serizawa M, Omae K, Kojima H, Nakashima K, Omori S, Wakuda K, Kenmotsu H, Naito T, et al. Corrigendum to "Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer" [Lung Cancer 128 (2019) 152-157]. Lung cancer (Amsterdam, Netherlands). 2019. 130. 226-226
Mitsuya K, Nakasu Y, Hayashi N, Deguchi S, Takahashi T, Murakami H, Naito T, Kenmotsu H, Ono A, Wakuda K, et al. Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study. PloS one. 2019. 14. 1. e0210074
Haruyasu Murakami, Akira Ono, Kazuhisa Nakashima, Shota Omori, Kazushige Wakuda, Hirotsugu Kenmotsu, Tateaki Naito, Toshiaki Takahashi. Long-term clinical outcomes of ALK inhibitors in patients with ALK-positive advanced non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. 2017. 35
Terufumi Kato, Fumikazu Sakai, Tomohisa Baba, Masahiko Kusumoto, Hirotsugu Kenmotsu, Hiroaki Sugiura, Junya Tominaga, Katsunori Oikado, Masafumi Sata, Masahiro Endo, et al. Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors for fatal outcome. JOURNAL OF CLINICAL ONCOLOGY. 2017. 35
Norimitsu Kasahara, Hirotsugu Kenmotsu, Masakuni Serizawa, Rina Umehara, Akira Ono, Kazushige Wakuda, Shota Omori, Kazuhisa Nakashima, Tetsuhiko Taira, Tateaki Naito, et al. Plasma epidermal growth factor receptor mutation (EGFR) testing in advanced non-small-cell lung cancer patients harboring EGFR mutations by chip-based digital PCR system. CANCER RESEARCH. 2016. 76
Hirotsugu Kenmotsu, Yusuke Tanigawara. Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose. CANCER SCIENCE. 2015. 106. 5. 497-504
Hisao Imai, Keita Mori, Akira Ono, Hiroaki Akamatsu, Takehito Shukuya, Tetsuhiko Taira, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Masahiro Endo, et al. RELATIONSHIP OF PROGRESSION-FREE SURVIVAL, POST-PROGRESSION SURVIVAL AND RESPONSE WITH OVERALL SURVIVAL IN ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER OF INDIVIDUAL-LEVEL. RESPIROLOGY. 2013. 18. 85-85
